---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-130432"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:10:26.551590+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# IN8bio appoints Jeremy Graff, Ph.D. as Class I director

## Summary
- Board expanded from six to seven directors; Graff appointed effective May 1, 2023, term expiring at 2025 annual meeting.
- Graff currently serves as Chief Scientific Officer of IMV, Inc.; previously President/CSO of Biothera Pharmaceuticals and Chief Development Officer at HiberCell.
- Graff will serve on Nominating & Corporate Governance Committee and chair the Science and Technology Committee.
- Compensation follows standard non-employee director policy; company entered into standard indemnification agreement with Graff.

## SEC filing metadata
- accession: 0001193125-23-130432
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/0001193125-23-130432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/d467270d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-130432
- JSON: https://secwatch.observer/filing/0001193125-23-130432.json
- Plain text: https://secwatch.observer/filing/0001193125-23-130432.txt

## Key facts
- Executive change
  Jeremy Graff, Ph.D. was appointed as Class I director at IN8BIO, INC..
  - Action: appointed
  - Role: Class I director
  source text: appointed Jeremy Graff, Ph.D., as a Class I director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/0001193125-23-130432-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.